.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Tiziana Musacchio

Further involvements

15/12/2022
11:50 – 11:55 5 Min.
ePoster Presentation
P 122
Real-World Clinical Utilization Differences of OnabotulinumtoxinA and AbobotulinumtoxinA in Upper Limb Spasticity
Movement disorders, Spasticity
15/12/2022
12:05 – 12:10 5 Min.
ePoster Presentation
P 099
Improved Disability and Quality of Life Outcomes in Hemiparetic Patients with Upper and Lower Limb Spasticity from Etiologies Other Than Stroke Treated with OnabotulinumtoxinA: Insights from the Adult Spasticity International Registry (ASPIRE) Study
Motor neurorehabilitation, Spasticity
15/12/2022
12:10 – 12:15 5 Min.
ePoster Presentation
P 102
OnabotulinumtoxinA treatment and physician and patient satisfaction in patients with spastic hemiparesis from ASPIRE
Movement disorders, Spasticity